文献速递眼底病与葡萄膜炎

Archway 3期试验:雷珠单抗端口给药系统治疗新生血管性年龄相关性黄斑变性2年结果

Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results.
PubMed 文献 · Ophthalmology · 2023-03-02

Archway 3期随机对照试验报告雷珠单抗端口给药系统(PDS)治疗新生血管性年龄相关性黄斑变性(nAMD)的2年结果。PDS每24周补充交换一次在视力改善上不劣于每月雷珠单抗注射,各补充交换间期约95%患者未接受补充治疗。预设眼部特别关注不良事件在PDS组更常见,但总体可控。

要点

  • PDS每24周补充交换在44/48、60/64、88/92周平均视力变化不劣于每月雷珠单抗。
  • 四个补充交换间期中98.4%、94.6%、94.8%、94.7%的PDS患者未接受补充雷珠单抗。
  • 预设眼部特别关注不良事件PDS组59例(23.8%)vs 每月雷珠单抗组17例(10.2%)。

核心结论

  • PDS每24周补充交换在约2年内显示不劣于每月雷珠单抗的疗效,各补充交换间期约95%患者未接受补充雷珠单抗治疗。
  • 特别关注不良事件总体可控,并持续落实经验以尽量减少PDS相关不良事件。

研究设计与样本

  • 3期、随机、多中心、开放标签、阳性对照试验。
  • 患者为筛选前9个月内诊断、既往接受过治疗且对抗血管内皮生长因子治疗有应答的nAMD患者。
  • 患者按3:2随机分配至PDS雷珠单抗100 mg/ml每24周固定补充交换(PDS Q24W)或玻璃体腔注射雷珠单抗0.5 mg每4周(每月雷珠单抗)。
  • 随访贯穿4个完整补充交换间期(约2年)。

主要发现

  • 第44/48周、60/64周、88/92周平均的校正后视力变化差值分别为-0.2(95%CI -1.8至+1.3)、+0.4(95%CI -1.4至+2.1)、-0.6(95%CI -2.5至+1.3)ETDRS字母。
  • 至第96周,两组解剖学结局总体相当。
  • 四个PDS补充交换间期中,评估的PDS Q24W患者分别有98.4%、94.6%、94.8%、94.7%未接受补充雷珠单抗治疗。
  • 预设眼部特别关注不良事件在PDS组59例(23.8%)、每月雷珠单抗组17例(10.2%)报告;两组最常见均为白内障(PDS Q24W 22例[8.9%],每月雷珠单抗10例[6.0%])。
  • PDS Q24W组事件包括结膜糜烂10例(4.0%)、结膜回缩6例(2.4%)、眼内炎4例(1.6%)、植入物移位4例(1.6%)。

关键数值与推荐

  • 主要结局为非劣效性检验,非劣效界值为-3.9 ETDRS字母。
  • PDS Q24W组与每月雷珠单抗组的校正后平均视力变化差值在三个时间段均未超过非劣效界值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report 2-year results from the Archway clinical trial of the Port Delivery System with ranibizumab (PDS) for treatment of neovascular age-related macular degeneration (nAMD). DESIGN: Phase 3, randomized, multicenter, open-label, active-comparator-controlled trial. PARTICIPANTS: Patients with previously treated nAMD diagnosed within 9 months of screening and responsive to anti-vascular endothelial growth factor therapy. METHODS: Patients were randomized 3:2 to PDS with ranibizumab 100 mg/ml with fixed refill-exchanges every 24 weeks (PDS Q24W) or intravitreal ranibizumab 0.5 mg injections every 4 weeks (monthly ranibizumab). Patients were followed through 4 complete refill-exchange intervals (∼2 years). MAIN OUTCOME MEASURES: Change in best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score from baseline averaged over weeks 44 and 48, weeks 60 and 64, and weeks 88 and 92 (noninferiority margin, -3.9 ETDRS letters). RESULTS: The PDS Q24W was noninferior to monthly ranibizumab, with differences in adjusted mean change in BCVA score from baseline averaged over weeks 44/48, 60/64 and 88/92 of -0.2 (95% confidence interval [CI], -1.8 to +1.3), +0.4 (95% CI, -1.4 to +2.1) and -0.6 ETDRS letters (95% CI, -2.5 to +1.3), respectively. Anatomic outcomes were generally comparable between arms through week 96. Through each of 4 PDS refill-exchange intervals, 98.4%, 94.6%, 94.8%, and 94.7% of PDS Q24W patients assessed did not receive supplemental ranibizumab treatment. The PDS ocular safety profile was generally unchanged from primary analysis. Prespecified ocular adverse events of special interest (AESI) were reported in 59 (23.8%) PDS and 17 (10.2%) monthly ranibizumab patients. The most common AESI reported in both arms was cataract (PDS Q24W, 22 [8.9%]; monthly ranibizumab, 10 [6.0%]). Events in the PDS Q24W arm included (patient incidence) 10 (4.0%) conjunctival erosions, 6 (2.4%) conjunctival retractions, 4 (1.6%) endophthalmitis cases, and 4 (1.6%) implant dislocations. Serum ranibizumab sampling showed that the PDS continuously released ranibizumab over the 24-week refill-exchange interval and ranibizumab serum concentrations were within the range experienced with monthly ranibizumab. CONCLUSIONS: The PDS Q24W showed noninferior efficacy to monthly ranibizumab through approximately 2 years, with approximately 95% of PDS Q24W patients not receiving supplemental ranibizumab treatment in each refill-exchange interval. The AESIs were generally manageable, with learnings continually implemented to minimize PDS-related AEs. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Regillo C, Berger B, Brooks L, et al. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023. PMID: 36870451. doi:10.1016/j.ophtha.2023.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。